GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (LTS:0IGA) » Definitions » PB Ratio

Emergent BioSolutions (LTS:0IGA) PB Ratio : 0.52 (As of Apr. 22, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Emergent BioSolutions PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-22), Emergent BioSolutions's share price is $4.6612. Emergent BioSolutions's Book Value per Share for the quarter that ended in Dec. 2024 was $8.89. Hence, Emergent BioSolutions's PB Ratio of today is 0.52.

The historical rank and industry rank for Emergent BioSolutions's PB Ratio or its related term are showing as below:

LTS:0IGA' s PB Ratio Range Over the Past 10 Years
Min: 0.13   Med: 2.13   Max: 5.89
Current: 0.52

During the past 13 years, Emergent BioSolutions's highest PB Ratio was 5.89. The lowest was 0.13. And the median was 2.13.

LTS:0IGA's PB Ratio is ranked better than
91.63% of 932 companies
in the Drug Manufacturers industry
Industry Median: 1.845 vs LTS:0IGA: 0.52

During the past 12 months, Emergent BioSolutions's average Book Value Per Share Growth Rate was -28.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -34.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -17.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -0.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Emergent BioSolutions was 135.90% per year. The lowest was -34.40% per year. And the median was 12.70% per year.

Back to Basics: PB Ratio


Emergent BioSolutions PB Ratio Historical Data

The historical data trend for Emergent BioSolutions's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions PB Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 1.44 0.42 0.33 1.05

Emergent BioSolutions Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.32 0.96 0.87 1.05

Competitive Comparison of Emergent BioSolutions's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's PB Ratio falls into.


;
;

Emergent BioSolutions PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Emergent BioSolutions's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=4.6612/8.886
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Emergent BioSolutions  (LTS:0IGA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Emergent BioSolutions PB Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions Business Description

Traded in Other Exchanges
Address
300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Headlines

No Headlines